DIabetes GLycemic Assessment in Newly Confirmed Episodes

This is a prospective, open-label, randomized controlled trial involving 80 adult patients with newly diagnosed T2DM (diagnosed within the last 3 months) recruited at the Bogomolets National Medical University. Participants may be lifestyle-controlled or receiving stable non-insulin anti-diabetic medications. Participants will be randomized in a 1:1 ratio to either the Real-Time Continuous Glucose Monitoring group (CGM group) or the control group (standard Self-Monitoring of Blood Glucose \[SMBG\] using conventional glucometers). The gathered data will help determine whether the real-time visual feedback provided by CGM systems superiorly improves glycemic variability, optimizes metabolic parameters, and enhances patient adherence to lifestyle interventions and pharmacological treatment compared to conventional SMBG methods in the early stages of T2D.

NCT Number	NCT07690163
Lead Sponsor	Nazarii Kobyliak Collaborators: COR-Medical LLC, Iridium LLC
Conditions	Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Insulin Resistance
Enrollment	80 participants
Start Date	2026-07-15
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-14